


JuRexMaximus
1.1K posts

@JuryRex
Clinical Trials Professional • He/Him • 🇵🇭🇬🇧🇲🇽









📢 M&A News: $GSK to Acquire $NUVL Deal Terms » $124/sh all-cash » ~$10.6B equity value » ~$9.4B net investment » Premium: 40% last close | 26% 30D VWAP Lead Assets » Zidesamtinib, ROS1 inhibitor » Neladalkib, ALK inhibitor » Indication: NSCLC » Stage: FDA review, 2026 PDUFA dates 🔍 BPIQ Lens » $GSK market cap: ~$101.5B » Deal size: ~10% of $GSK market cap » $NUVL up ~39% on the deal » BPIQ suspected mover: Zidesamtinib PDUFA, Sept. 18, 2026 Strategic Fit » Accelerates $GSK entry into lung cancer » Adds 2 potential best-in-class NSCLC assets » Complements GSK’s Ph3 B7-H3 ADC, Ris-Rez Timeline » Expected close: Q3 2026

a standing ovation for daraxonrasib at asco. over 40k oncologists, entrepreneurs, investors, and patient advocates together celebrating revmed's breakthru in the fight against pancreatic cancer. u never forget these moments. it's what innovation is all about.

Today I'm posting a new blog about an astonishing scientific own goal. Hundreds of papers have reported using a completely wrong antibody to investigate the tumor suppressor p16. This mistake has happened because scientists have muddled the names of two proteins 🧵









Paulit-ulit na to ha.

A majority of Filipinos, or 69 percent, support an impeachment trial against Vice President Sara Duterte, according to OCTA Research’s 2026 Tugon ng Masa survey. READ MORE: inqnews.net/majoritybackim…


